GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Beneish M-Score
中文

Repligen (Repligen) Beneish M-Score

: -2.57 (As of Today)
View and export this data going back to 1986. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Repligen's Beneish M-Score or its related term are showing as below:

RGEN' s Beneish M-Score Range Over the Past 10 Years
Min: -2.87   Med: -2.48   Max: -1.25
Current: -2.57

During the past 13 years, the highest Beneish M-Score of Repligen was -1.25. The lowest was -2.87. And the median was -2.48.


Repligen Beneish M-Score Historical Data

The historical data trend for Repligen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -1.94 -1.73 -2.50 -2.57

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.50 -2.42 -2.50 -2.65 -2.57

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen Beneish M-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Repligen's Beneish M-Score falls into.



Repligen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Repligen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3403+0.528 * 1.275+0.404 * 1.0264+0.892 * 0.7969+0.115 * 0.7986
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2681+4.679 * -0.043369-0.327 * 1.3266
=-2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $124.2 Mil.
Revenue was 155.743 + 141.192 + 159.169 + 182.66 = $638.8 Mil.
Gross Profit was 67.607 + 36.558 + 79.862 + 100.815 = $284.8 Mil.
Total Current Assets was $1,111.0 Mil.
Total Assets was $2,824.4 Mil.
Property, Plant and Equipment(Net PPE) was $323.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $68.1 Mil.
Selling, General, & Admin. Expense(SGA) was $218.1 Mil.
Total Current Liabilities was $158.2 Mil.
Long-Term Debt & Capital Lease Obligation was $636.7 Mil.
Net Income was -25.488 + 18.172 + 20.064 + 28.829 = $41.6 Mil.
Non Operating Income was -0.727 + 41.849 + 4.701 + 4.328 = $50.2 Mil.
Cash Flow from Operations was 29.065 + 39.231 + 34.468 + 11.154 = $113.9 Mil.
Total Receivables was $116.2 Mil.
Revenue was 186.762 + 200.741 + 207.633 + 206.4 = $801.5 Mil.
Gross Profit was 96.062 + 114.227 + 121.373 + 124.044 = $455.7 Mil.
Total Current Assets was $998.1 Mil.
Total Assets was $2,524.7 Mil.
Property, Plant and Equipment(Net PPE) was $315.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $51.0 Mil.
Selling, General, & Admin. Expense(SGA) was $215.8 Mil.
Total Current Liabilities was $404.2 Mil.
Long-Term Debt & Capital Lease Obligation was $131.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(124.161 / 638.764) / (116.247 / 801.536)
=0.194377 / 0.14503
=1.3403

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(455.706 / 801.536) / (284.842 / 638.764)
=0.568541 / 0.445927
=1.275

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1111.043 + 322.955) / 2824.411) / (1 - (998.118 + 315.696) / 2524.658)
=0.492284 / 0.479607
=1.0264

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=638.764 / 801.536
=0.7969

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(50.985 / (50.985 + 315.696)) / (68.085 / (68.085 + 322.955))
=0.139045 / 0.174113
=0.7986

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(218.113 / 638.764) / (215.829 / 801.536)
=0.341461 / 0.269269
=1.2681

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((636.721 + 158.162) / 2824.411) / ((131.389 + 404.196) / 2524.658)
=0.281433 / 0.212142
=1.3266

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(41.577 - 50.151 - 113.918) / 2824.411
=-0.043369

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Repligen has a M-score of -2.57 suggests that the company is unlikely to be a manipulator.


Repligen Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Repligen's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453